Vyvron Microdose Review: $149 Every 4 Weeks, Not Monthly

Vyvron sells microdosing as its own program, with its own name, its own page and its own price — not as a footnote on a weight-loss plan. That alone puts it in a small group. We read the site in August 2026, and the interesting thing about it is not the price. It is the unit the price is quoted in.

This is an editorial review. Vyvron is not a partner of ours, there is no affiliate link anywhere on this page, and it is not ranked on our GLP-1 microdose rankings hub.

The number, and the number underneath it

The microdosing program is advertised at a founding rate of $149, against a stated post-founding list rate of $179. Both are printed with a "/mo" suffix. Neither is a monthly price.

Vyvron's own fine print says plans are billed every four weeks, auto-renewing until you cancel. Four-week cycles do not divide a year into twelve. They divide it into thirteen.

So the founding microdosing rate costs $1,937 a year, not $1,788 — one extra charge of $149 that nothing on the page prepares you for. At the weight-loss program's $199 rung the same arithmetic runs $2,587 against an implied $2,388. This is not a rounding artefact and it is not a hidden fee in the usual sense: every individual disclosure is accurate. It is a mislabeled unit, and a mislabeled unit compounds quietly for exactly as long as you stay enrolled — which, for someone microdosing as a maintenance habit, is meant to be a long time. We put that kind of qualified figure next to the ones it competes with in what microdosing GLP-1 costs.

Which $149? The site says two things

The homepage program cards advertise microdosing at "$179/mo". The microdosing program page says $149. Those are not two rungs of a ladder; they are the same rung quoted twice, and one of them is wrong.

The $179 is the post-founding list price — the rate that applies once founding pricing closes — rendered on the homepage as though it were the price today. We file $149, because the program page is where the enrollment call to action and the billing disclosure both live, and a price on a card that does not transact is a claim rather than an offer. But a reader who never leaves the homepage is looking at a number $30 above what the enrollment page charges, and neither surface acknowledges the other.

Does the microdose cost less than the full program?

At the program level, yes: $149 per four weeks against $199 per four weeks for Medical Weight Loss, a $50 gap per cycle. Post-founding, $179 against $249.

But note what that comparison is and is not. These are two separate programs, not two doses of one — and Vyvron does not publish a dose, a milligram figure or a route for the microdosing line, describing it only as low-dose GLP-1 combinations. So you can price the low dose here; you cannot see what quantity of drug the lower price buys you, or check the ratio between them. That is a weaker version of the structure we are looking for than a company that prints a microdose rung directly beneath its own standard rung on the same molecule — Auren Rx does exactly that on both semaglutide and tirzepatide, and the difference is that you can audit it.

One structural fact from the weight-loss side is worth carrying over, because it tells you how this company thinks about pricing: there is no month-to-month tirzepatide plan at all. The only recurring rung on the weight-loss ladder is semaglutide. The tirzepatide tiers display "$285/mo" and "$248/mo" but are billed once — $790 for twelve weeks and $2,981 for a year. The "$285/mo" divides $790 across roughly 2.77 calendar months; across three four-week cycles it is $263. Two different "per month" conventions are in use inside a single pricing table.

Two hype signals, named plainly

The founding-member counter does not count. "100 of 100 founding spots left" sits above a progress bar rendered at full width. Both are hardcoded constants. The bar will never move and the number will never fall, whatever happens to enrollment. It is scarcity as decoration.

The testimonials are placeholders — the site states that patient stories will appear once founding members give written consent. That is honest, and we will say so. It is also an unambiguous statement that this company has no track record yet, which is worth holding next to the founding-price urgency the rest of the page is built on. We take apart the wider genre of microdose marketing signals in is microdosing GLP-1 legit or hype.

Credit where it is due

Vyvron discloses its geography better than most companies twice its age. All fifty states plus DC; a video visit required in Arkansas, DC, Delaware, Kansas, Mississippi, New Mexico, Rhode Island and West Virginia; and compounded GLP-1 explicitly not available in Mississippi, branded only. That last line is the kind of specific, commercially inconvenient detail most operators leave out entirely.

The clinical layer is OpenLoop Health, Inc. and its affiliated professional entities — a real, substantial telehealth infrastructure company, and the strongest thing on the site.

What it will not tell you, and when it takes your money

No pharmacy is named. No prescriber is named and no NPI is published. The legal entity is Vyvron, LLC at 30 N Gould St in Sheridan, Wyoming — the most heavily used registered-agent mail drop in the United States, and not an operating location.

You are charged when you complete the intake, before a provider reviews it. A full refund is available only if you cancel within 72 hours with no services rendered, or if a provider medically disqualifies you. Canceling otherwise requires 72 hours' notice before the next billing date or you are charged for that cycle. Prepaid plans refund only the months whose medication has not shipped.

The regulatory screen

Vyvron and its clinical partner both returned zero company-column matches in the FDA's live warning-letter index in August 2026.² The screen carried a positive control — an unrelated telehealth seller with a real 2026 letter — which returned correctly every time, so the zeros are evidence rather than a broken query.

The standing caveat this site never drops

No randomized controlled trial has tested below-label GLP-1 dosing for weight loss, glycemic control or safety. The only clinical literature addressing microdosing directly does so as a caution, describing a practice that emerged amid compounding restrictions on patient anecdote rather than tested protocol.³ Vyvron naming and separately pricing a microdosing program is a commercial decision, not a clinical finding, and a founding-member rate does not make an untested regimen better value — it makes it a cheaper untested regimen. See does microdosing GLP-1 work for what the dose-response data actually imply.

The honest bottom line

Vyvron gets two hard things right that most of this market gets wrong: it runs microdosing as a genuinely separate, separately priced program, and it discloses its state-by-state limits in unusual detail with a real clinical partner behind it. It gets one thing wrong that undoes a lot of that — it prices in four-week cycles and prints "/mo", so the true annual cost carries a thirteenth charge nobody budgets for. Add a homepage that quotes a different price from the enrollment page, a scarcity counter that cannot move, an unnamed pharmacy, no named prescriber, and a charge taken before anyone clinical has looked at you. If you go ahead, multiply by thirteen and use the program page's number, not the homepage's.